Citius Oncology (CTOR) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing targeted oncology therapies, leveraging new formulations or expanded indications of previously approved drugs to reduce development risk and secure IP/regulatory exclusivity.

• Lead product, LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, targets persistent or recurrent CTCL and was FDA-approved in August 2024, launched December 2025.

• Commercialization strategy includes direct U.S. sales and ex-U.S. partnerships, with a targeted oncology sales force focused on major cancer centers.

• Became a standalone public company via a reverse merger in August 2024, with Citius Pharmaceuticals retaining a significant ownership stake.

Financial performance and metrics

• December 2025 offering raised approximately $18.0 million in gross proceeds before fees and expenses.

• September 2025 and July 2025 offerings each raised approximately $9.0 million in gross proceeds before fees and expenses.

• If all warrants and pre-funded warrants are exercised for cash, potential gross proceeds could total up to $27.9 million.

Use of proceeds and capital allocation

• Company will not receive proceeds from the resale of shares by selling stockholders.

• May receive proceeds from the cash exercise of warrants, pre-funded warrants, and placement agent warrants, with all such proceeds allocated to working capital.